MétaCan
Menu
Back to cohort
Record W4406512218 · doi:10.1371/journal.pone.0313741

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

2025· article· en· W4406512218 on OpenAlexafffund
Shakila Meshkat, Richard J. Zeifman, Kathleen E. Stewart, Reinhard Janssen‐Aguilar, Wendy Lou, Rakesh Jetly, Candice M. Monson, Venkat Bhat

Bibliographic record

VenuePLoS ONE · 2025
Typearticle
Languageen
FieldPsychology
TopicPsychedelics and Drug Studies
Canadian institutionsRoyal Ottawa Mental Health CentreUniversity of OttawaUniversity of TorontoToronto Metropolitan UniversityPublic Health OntarioSt. Michael's Hospital
FundersCanadian Institutes of Health ResearchEisaiUniversity of TorontoAssociated Medical ServicesGovernment of CanadaRoyal College of Physicians and Surgeons of CanadaAmerican Foundation for Suicide Prevention
KeywordsPsilocybinPosttraumatic stressMedicineCognitionCognitive processing therapyCognitive behavioral therapyHallucinogenPsychiatryPsychology

Abstract

fetched live from OpenAlex

BACKGROUND: Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonstrated efficacy in treating chronic PTSD, a substantial proportion of patients still continue to meet PTSD criteria after treatment, highlighting the need for novel therapeutic approaches. Preliminary evidence supports the potential therapeutic action of psilocybin to alleviate PTSD symptoms. This open-label pilot study aims to evaluate the feasibility, tolerability, and preliminary efficacy of a single dose 25 mg psilocybin in combination with one week of massed CPT in patients with chronic PTSD. METHOD: Fifteen participants with chronic PTSD will undergo 12 CPT sessions, two psilocybin-related psychotherapy sessions, and one psilocybin dosing session over a 7-days period. The primary outcomes are feasibility and tolerability, which will be measured by recruitment rates, withdrawal, data completion, adherence, number and nature of adverse events. Secondary objectives include assessing the preliminary efficacy of psilocybin-assisted CPT in reducing PTSD severity, self-reported treatment outcomes and exploring putative mechanisms of change. Participants will be monitored weekly for 12 weeks post-treatment and passive data relevant to mental health and well-being will be collected using a wearable device. DISCUSSION: This trial will generate important preliminary data on the use of psilocybin-assisted CPT for treating PTSD. The findings will guide the design of a multi-site, large-scale randomized control trial to more rigorously assess the efficacy of this intervention. De-identified data from this study will be available upon request after publication of the results. This study represents a promising and innovative approach to PTSD treatment, potentially offering an alternative therapeutic option for individuals unresponsive to conventional therapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT06386003.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.022
metaresearch head score (Gemma)0.016
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.044
Threshold uncertainty score0.148

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0220.016
Meta-epidemiology (narrow)0.0040.002
Meta-epidemiology (broad)0.0060.002
Bibliometrics0.0020.002
Science and technology studies0.0040.003
Scholarly communication0.0030.002
Open science0.0040.002
Research integrity0.0050.008
Insufficient payload (model declined to judge)0.0440.010

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.413
GPT teacher head0.489
Teacher spread0.075 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2025
Admission routes2
Has abstractyes

Explore more

Same venuePLoS ONESame topicPsychedelics and Drug StudiesFrench-language works237,207